Additionally, there is higher expression of SMO and Gli1 in borderline and malignant tumor tissues than in benign tumor and normal ovarian tissues [63–64], indicating their importance in progression of ovarian cancer. This evidence concerns the gene GLI1 and ovarian cancer.